My guess is there was likely some discussion with the FDA around the rosuvastatin/atorvastatin topic vis a vis outcomes before BoM even began. I remember way back Don saying that initially RVX wanted this trial to be Apabetalone + rosuvastatin only but atorvastatin was included at the request of the FDA.